JSMO 2023 - The 20th Annual Meeting of Japanese Society of Medical Oncology
Mar 16 - Mar 18, 2023 | FukuokaJapan
LARVOL is not affiliated with The 20th Annual Meeting of Japanese Society of Medical Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 59 titles linked to Trials
Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM
Discussion
Presidential Session 4Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412
Discussion
Presidential Session 3Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2
Discussion
Presidential Session 3Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma (R/RMCL) in ZUMA-2: Durable Responder Analysis
Discussion
Presidential Session 3Efficacy and safety of fruquintinib in Japanese patients with refractory metastatic colorectal cancer from FRESCO-2
Discussion
Presidential Session 4MOMENTUM: Phase 3 Study of Momelotinib vs Danazol in Symptomatic and Anemic Myelofibrosis Patients post-JAK Inhibition
Discussion
Presidential Session 3PD-1 blockade as curative intent therapy in mismatch repair deficient locally advanced rectal cancer
Discussion
Presidential Session 4First Report of Cohort 3 and Mature Survival Data From the U31402-A-U102 Study of HER3‑DXd in EGFR-Mutated NSCLC
Sotorasib versus Docetaxel for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation: CodeBreaK 200 Phase 3 Study
Adjuvant osimertinib in resected EGFR-mutated stage II–IIIA NSCLC: ADAURA Japan subgroup analysis
Phase II study of brigatinib in patients with TKI-naive ROS1-rearranged non-small cell lung cancer (NSCLC):Barossa study.
Phase 1b Efficacy of Telisotuzumab Vedotin and Osimertinib in Asian vs Non-Asian Patients With Advanced NSCLC
TROPION-Lung02: Initial Results of Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Overall survival results from the phase 3 TROPiCS-02 study of sacituzumab govitecan vs chemotherapy in HR+/HER2- mBC
T-DXd vs treatment of physician's choice in HER2+ mBC previously treated with T-DM1: primary results of DESTINY-Breast02